March 23, 2010

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

.   .   

This RCT randomized patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo in addition to lifestyle modification. No reduction in cardiovascular events was noted at 5 years, but the incidence of diabetes was reduced; 33.1% in the valsartan group vs 36.8% in the placebo group (HR 0.86, p<0.001).

Related Articles:

Diabetes, RAS Blockade

Comments are closed.